Mary JD - Dice Molecules G Counsel
Insider
Mary JD is G Counsel of Dice Molecules Holdings
| Phone | 650 566 1402 |
| Web | https://www.dicemolecules.com |
Dice Molecules Management Efficiency
The company has return on total asset (ROA) of (0.1402) % which means that it has lost $0.1402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.216) %, meaning that it created substantial loss on money invested by shareholders. Dice Molecules' management efficiency ratios could be used to measure how well Dice Molecules manages its routine affairs as well as how well it operates its assets and liabilities.Dice Molecules Holdings currently holds 13.27 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Dice Molecules Holdings has a current ratio of 23.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Dice Molecules' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ashish MBA | Vaxcyte | 53 | |
| Michael Carruthers | Edgewise Therapeutics | 67 | |
| Sbastien Desprez | Immunocore Holdings | N/A | |
| Dean MD | Pliant Therapeutics | N/A | |
| Kari JD | Cytokinetics | N/A | |
| Neeraj Teotia | Arcellx | 50 | |
| Kristian Reich | MoonLake Immunotherapeutics | 59 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Carrie MBA | Viridian Therapeutics | N/A | |
| Margaret MBA | Amylyx Pharmaceuticals | 59 | |
| Narinderjeet MS | Arcellx | 53 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Karen Alderete | Vaxcyte | N/A | |
| MBA MD | Viridian Therapeutics | 72 | |
| Russell MS | Acumen Pharmaceuticals | 67 | |
| Timothy Lee | Ascendis Pharma AS | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| Nuala Brennan | MoonLake Immunotherapeutics | N/A | |
| Bill DeGrado | Pliant Therapeutics | N/A | |
| Christopher MD | Arcellx | 45 | |
Management Performance
| Return On Equity | -0.22 | |||
| Return On Asset | -0.14 |
Dice Molecules Holdings Leadership Team
Elected by the shareholders, the Dice Molecules' board of directors comprises two types of representatives: Dice Molecules inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dice. The board's role is to monitor Dice Molecules' management team and ensure that shareholders' interests are well served. Dice Molecules' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dice Molecules' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Judice, CEO Founder | ||
| Scott Robertson, Chief Officer | ||
| Timothy MD, Chief Officer | ||
| John Jacobsen, Chief Officer | ||
| Mary JD, G Counsel | ||
| Venkat Thalladi, VP CMC | ||
| Paul Fatheree, VP Chemistry |
Dice Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dice Molecules a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | 2.27 B | |||
| Shares Outstanding | 47.76 M | |||
| Shares Owned By Insiders | 3.15 % | |||
| Shares Owned By Institutions | 96.85 % | |||
| Number Of Shares Shorted | 4.88 M | |||
| Price To Book | 5.91 X | |||
| Price To Sales | 699.00 X | |||
| Gross Profit | (56.08 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Dice Stock
If you are still planning to invest in Dice Molecules Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dice Molecules' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |